GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Teleflex Inc (NYSE:TFX) » Definitions » ROE %

Teleflex (Teleflex) ROE %

: 2.84% (As of Dec. 2023)
View and export this data going back to 1994. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Teleflex's annualized net income for the quarter that ended in Dec. 2023 was $124 Mil. Teleflex's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $4,378 Mil. Therefore, Teleflex's annualized ROE % for the quarter that ended in Dec. 2023 was 2.84%.

The historical rank and industry rank for Teleflex's ROE % or its related term are showing as below:

TFX' s ROE % Range Over the Past 10 Years
Min: 6.68   Med: 10.22   Max: 16.72
Current: 8.44

During the past 13 years, Teleflex's highest ROE % was 16.72%. The lowest was 6.68%. And the median was 10.22%.

TFX's ROE % is ranked better than
69.83% of 812 companies
in the Medical Devices & Instruments industry
Industry Median: 0.27 vs TFX: 8.44

Teleflex ROE % Historical Data

The historical data trend for Teleflex's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Teleflex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.72 10.62 13.69 9.34 8.42

Teleflex Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.94 7.55 10.70 12.86 2.84

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Teleflex's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Teleflex ROE % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Teleflex's ROE % distribution charts can be found below:

* The bar in red indicates where Teleflex's ROE % falls into.



Teleflex ROE % Calculation

Teleflex's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=356.328/( (4021.968+4440.988)/ 2 )
=356.328/4231.478
=8.42 %

Teleflex's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=124.42/( (4314.048+4440.988)/ 2 )
=124.42/4377.518
=2.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Teleflex  (NYSE:TFX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=124.42/4377.518
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(124.42 / 3095.636)*(3095.636 / 7513.09)*(7513.09 / 4377.518)
=Net Margin %*Asset Turnover*Equity Multiplier
=4.02 %*0.412*1.7163
=ROA %*Equity Multiplier
=1.66 %*1.7163
=2.84 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=124.42/4377.518
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (124.42 / 239.888) * (239.888 / 539.632) * (539.632 / 3095.636) * (3095.636 / 7513.09) * (7513.09 / 4377.518)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.5187 * 0.4445 * 17.43 % * 0.412 * 1.7163
=2.84 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Teleflex ROE % Related Terms

Thank you for viewing the detailed overview of Teleflex's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Teleflex (Teleflex) Business Description

Traded in Other Exchanges
Address
550 East Swedesford Road, Suite 400, Wayne, PA, USA, 19087
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2022 sales), interventional (16%), anesthesia (14%), surgical (14%), interventional urology (12%), original-equipment manufacturing (10%), and all other (10%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.
Executives
Liam Kelly officer: EVP & President, International IDA BUSINESS AND TECHNOLOGY PARK, DUBLIN ROAD, ATHLONE L2 00000
Thomas E Powell officer: Senior Vice President & CFO C/O TOMOTHERAPY INCORPORATED, 1240 DEMING WAY, MADISON WI 53717
Stuart A Randle director 585 WEST 500 SOUTH, BOUNTIFUL UT 84010
Jaewon Ryu director 950 N. GLEBE ROAD, SUITE 700, ARLINGTON VA 22203
Neena M Patil director JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304
Andrew A Krakauer director CANTEL MEDICAL CORP., 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Cameron P Hicks officer: Vice President, Global HR 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Klasko Stephen K. M.d. director 155 SOUTH LIMERICK ROAD, LIMERICK PA 19468
Jay White officer: VP & Pres, Global Commercial 3015 CARRINGTON MILL BLVD., MORRISVILLE NC 27560
Daniel V. Logue officer: VP, Gen Counsel & Secretary 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
John Deren officer: VP & Chief Accounting Officer 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
James J Leyden officer: VP, General Counsel, Secretary C/O INFRASOURCE SERVICES, INC, 500 WEST DUTTON MILL ROAD, ASTON PA 19014
James Winters officer: Vice President, Mfg and Supply 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Mario Wijker officer: Vice President, QARA 550 E. SWEDESFORD ROAD, SUITE 400, WAYNE PA 19087
Benson Smith director C/O ROCHESTER MEDICAL INC, ONE ROCHESTER MEDICAL DDRIVE, STEWARTVILLE MN 55976

Teleflex (Teleflex) Headlines